Skip to content

Seaport Therapeutics SPTX Additional Paid-In Capital

Additional Paid-In Capital at other companies

MYR Group logo
MYR GroupMYRG
$162.37M+6.2%
Piper Sandler logo
Piper SandlerPIPR
$1B+1.7%
Repligen logo
RepligenRGEN
$1.65B+2.2%
LKQ logo
LKQLKQ
$1.58B+1.7%
ST
Sensata TechnologiesST
$1.9B+1.3%
CHE
ChemedCHE
$1.6B+4.2%

Other financials

Income statement

See full
Operating income-$27.5M-70.2%
Net income-$25.4M-93.6%
EPS (diluted)-$10.34-83.0%

Balance sheet

See full
Cash & equivalents$52.9M
Total debt$5.3M
Total equity-$115.6M-220%
Total assets$227.7M

Cash flow

See full
Operating cash flow-$20.2M+0.2%
CapEx--100%
Free cash flow-$20.2M+0.4%

Valuation

See full
Market cap$972.65M
Enterprise value$925.08M

Returns & leverage

See full
Debt / equity-0×
Current ratio13.2×

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Seaport Therapeutics 's additional paid-in capital?
Seaport Therapeutics (SPTX) reported additional paid-in capital of $23.83M in Q1 2026.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.